IPFnet is a network of research centers dedicated to the study of idiopathic pulmonary fibrosis (IPF). The network’s goal is to find effective therapies for patients with both the early and advanced stages of this devastating disease.
Pulmonary fibrosis, a progressive scarring of the lung, makes it difficult for patients to breathe. "Idiopathic" means the medical community does not yet understand its cause. IPF is a relentless disease, stubborn in its resistance to treatment. Shortness of breath typically worsens gradually, but episodes of severe deterioration can occur from time to time. Unfortunately, IPF is often fatal within a few years of diagnosis.
Centers of excellence are 26 medical centers across the United States that excel in the treatment of IPF. These medical centers make up the IPF network, along with Duke University, which serves as the coordinator of the network. Under the guidance of the National Heart Lung and Blood Institute, these centers will develop and conduct clinical trials that will hopefully identify better therapies for IPF, in both its early and advanced stages.